Abstract 27P
Background
Unlike other types of cancer that are sensitive to single-target agents, such as lung cancer and chronic myeloid leukemia, colorectal cancer (CRC) involves a complex network of interactions between activating oncogenes and is thus more likely to respond to multi-target therapy. Approximately 10% of CRC mutations are within the BRAF gene, the most frequent being BRAFV600E. While this mutation can be targeted with relatively high efficacy by single-target therapies, there exists a cohort of atypical BRAF mutations that confer higher resistance to currently available treatments. Furthermore, a large proportion of these atypical BRAF mutations are poorly understood.
Methods
We used principal component analysis and semi-supervised clustering learning methods to classify mutants unassigned by the previous BRAF classification system. By leveraging previously established protein-protein networks, we overlaid them with gene essentiality data to successfully classify 84 new BRAF mutations. We then evaluated the oncogenic potential of the newly classified atypical class-2 or -3 BRAF mutations compared to wild-type and class-1 BRAF mutations to validate that our extended system was consistent with the previously established BRAF classes. We also performed a network analysis to determine which genes were co-mutated for each BRAF class.
Results
Cell viability analysis of the BRAF-mutant Ba/F3 cells yielded no significant differences in the median AUC values between the new and old classification systems. Several key genes (including PIK3CA, EGFR, and MEK) were identified as potential drug targets (IC 50: 0.1 μM) for cell lines with class-2 and -3 atypical BRAF mutations. We found that atypical BRAF mutations have significantly more positive CERES scores than class-1 mutations and thus need to partner with other oncogenes to drive oncogenesis due to their lower oncogenic potential.
Conclusions
In conclusion, we extended the previous Yao classification system to establish a more comprehensive BRAF-mutant classification system, Yao Classification System Plus, that encompasses more atypical BRAF mutations. This allows for greater therapeutic options to target cells carrying these previously uncharacterized mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Texas MD Anderson Cancer Center.
Funding
National Cancer Institute , the Cancer Center Support Grant, and the Cancer Prevention & Research Institute of Texas.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09